Skip to main content

Table 3 Associations between rosiglitazone use and gastric cancer risk in a population-based nested case–control study

From: Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study

Variables

Rosiglitazone

Cases

Controls

Crude OR

Adjusted OR

Adjusted OR

N = 357

%

N = 1,428

%

Nonuse

323

90.5

1,217

85.2

1.00

1.00

1.00

Any use

34

9.5

211

14.8

0.61*

0.75

1.21

  Recent use

10

2.8

25

1.8

1.51

1.50

1.88

  Past use

24

6.7

186

13.0

0.49*

0.62*

0.93

Cumulative dosage

 

  < 260 DDDs

23

6.4

94

6.6

0.92

1.14

1.69

  ≥ 260 DDDs

11

3.1

117

8.2

0.35*

0.44*

0.79

Cumulative duration

 

  < 1 year

26

7.3

116

8.1

0.85

1.04

1.56

  ≥ 1 year

8

2.2

95

6.7

0.32*

0.40*

0.74

  1. : Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, and comorbidities.
  2. : Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, comorbidities, and medications.
  3. OR odds ratios, N number.
  4. *P < 0.05.